Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia
Authors:
- Marta TenutaMarta Tenuta
- Carla PandozziCarla Pandozzi
- Francesca SciarraFrancesca Sciarra
- Federica CampoloFederica Campolo
- Alain J. GelibterAlain J. Gelibter
- Grazia SirgiovanniGrazia Sirgiovanni
- Enrico CortesiEnrico Cortesi
- Andrea LenziAndrea Lenzi
- Andrea M. IsidoriAndrea M. Isidori
- Emilia SbardellaEmilia Sbardella
- Mary Anna VenneriMary Anna Venneri
Open Access
Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational study was to analyze peripheral blood mononuclear cells (PBMCs) in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICIs in order to identify predictive factors for better survival outcomes. Methods: Forty-seven stage IV NSCLC patients were enrolled. Patients underwent baseline (T0) and longitudinal (T1) evaluations after ICIs. Peripheral immune blood cell counts were analyzed using flow cytometry. Results: Basal levels of CD3−CD56+ NK cells were higher in patients with controlled disease (DC) compared to progression disease (PD) patients (127 cells/µL vs. 27.8 cells/µL, p < 0.001). Lower NK cell values were independent prognostic factors for shorter overall survival (OS) (HR 0.992; 95% CI 0.987–0.997, p < 0.001) and progression-free survival (PFS) (HR 0.988; 95% CI 0.981–0.994, p < 0.001). During the longitudinal evaluation, CD3−CD56+ NK cells (138.1 cells/µL vs. 127 cells/µL, p = 0.025) and CD56bright NK cells (27.4 cells/µL vs. 18.1 cells/µL, p = 0.034) significantly increased in the DC group. Finally, lower values of CD3−CD56+ NK cells (28.3 cells/µL vs. 114.6 cells/µL, p = 0.004) and CD56dim NK cells (13.2 cells/µL vs. 89.4 cells/µL, p < 0.001) were found in sarcopenic patients compared to patients without sarcopenia. Conclusions: Peripheral NK cells could represent a non-invasive and useful tool to predict ICI therapy response in NSCLC patients, and the association of low NK cell levels with sarcopenia deserves even more attention in clinical evaluation.Keywords
Funding Information
- Ministry of Health, Uganda (NET-2018-12365454, 2020FYCCE3)
- MIUR (NET-2018-12365454, 2020FYCCE3)
This publication has 68 references indexed in Scilit:
- Immunological and nutritional factors in elderly people in low-level care and their association with mortalityImmunity & Ageing, 2013
- Interleukin‐15 Affects Differentiation and Apoptosis in Adipocytes: Implications in ObesityLipids, 2011
- Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by ChemotherapyClinical Cancer Research, 2011
- Regulation of human NK-cell cytokine and chemokine production by target cell recognitionBlood, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?Cancer Research, 2008
- Interleukin-15: A muscle-derived cytokine regulating fat-to-lean body composition1,2Journal of Animal Science, 2008
- Perforin-mediated target-cell death and immune homeostasisNature Reviews Immunology, 2006
- Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-β–Mediated Suppressive Activity on T LymphocytesCancer Research, 2006
- Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cellsMolecular Immunology, 2005